Newsroom

Sorted by: Latest

-

Insulated Envelopes Market Analysis, Trends and Growth Outlook 2025-2030 - Rising Demand for Compact, Flat-Pack Solutions in Urban Logistics Encourages Use of Flexible Insulated Envelopes - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Insulated Envelopes - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Insulated Envelopes was valued at US$302.4 Million in 2024 and is projected to reach US$346.3 Million by 2030, growing at a CAGR of 2.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. Growth in the insulated envelopes mark...
-

LifeSpeak Assembles Industry's First AI-to-Behavior Science Advisory Team to Reimagine Digital Wellness

MINNEAPOLIS--(BUSINESS WIRE)--LifeSpeak assembles advisory team of eight leaders from Harvard Medical School, Stanford, IBM Watson and major media innovators...
-

Sutherland e ComplyAdvantage lançam solução nativa de IA para "Conformidade Unificada contra Crimes Financeiros" para combater crimes financeiros sofisticados de última geração

ROCHESTER, NOVA YORK.--(BUSINESS WIRE)--Sutherland, líder global em transformação digital e de negócios, anunciou hoje uma parceria estratégica com a ComplyAdvantage, plataforma líder em inteligência de risco baseada em IA. A colaboração introduz uma solução abrangente, Solução de gestão de crimes financeiros (FinCrime) baseada em IA projetada para ajudar bancos e fintechs a responder ao rápido aumento de fraudes criadas por IA, riscos complexos de lavagem de dinheiro, ameaças de crimes finance...
-

Copiers: Global Market Intelligence and Company Benchmarks 2025-2030 Featuring 41 Players - Canon, HP, Panasonic, Xerox, ZTE and More - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Copiers Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Copiers was valued at US$738 Million in 2024 and is projected to reach US$880.7 Million by 2030, growing at a CAGR of 3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The growth in the copiers market is driven by several inter...
-

Riassunto: Gestire la complessità e aumentare l'efficienza: CES 2026: dSPACE dimostra soluzioni di test e intelligenza artificiale per lo sviluppo di SDV

PADERBORN, Germania e LAS VEGAS--(BUSINESS WIRE)--Al CES 2026, dSPACE presenterà soluzioni complete di test che consentono ai produttori di veicoli di gestire in modo efficiente la sempre maggiore complessità nello sviluppo di veicoli definiti da software. Allo stand 4500 di West Hall, dSPACE illustrerà un portafoglio di convalida completo con soluzioni di software-in-the-loop e hardware-in-the-loop su base IA per lo sviluppo accelerato di veicoli. L'IA è un facilitatore strategico nell'intero...
-

Samenvatting: RoslinCT en Ayrmid Ltd. kondigen de uitbreiding van hun strategisch partnerschap aan om Omisirge® te produceren (omidubicel-onlv) voor een tweede door de FDA-goedgekeurde indicatie bij ernstige aplastische anemie (SAA)

BOSTON--(BUSINESS WIRE)--Ayrmid Ltd., het moederbedrijf van Gamida Cell Inc., een baanbrekend celtherapiebedrijf dat cellen omzet in krachtige therapeutica, en RoslinCT, een wereldleider in contractontwikkeling en -productie voor cel- en gentherapie, kondigden vandaag de uitbreiding van hun strategische partnerschap aan middels de uitvoering van een commerciële leveringsovereenkomst ter ondersteuning van de productie van Omisirge® (omidubicel-onlv). Deze bekendmaking is officieel geldend in de...
-

RoslinCT und Ayrmid Ltd. geben die Erweiterung ihrer strategischen Partnerschaft zur Herstellung von Omisirge® (Omidubicel-onlv) für die zweite von der FDA zugelassene Indikation bei schwerer aplastischer Anämie (SAA) bekannt

BOSTON, Massachusetts, USA--(BUSINESS WIRE)--Ayrmid Ltd. – die Muttergesellschaft von Gamida Cell Inc., einem wegweisenden Zelltherapieunternehmen, das Zellen in hochwirksame Therapeutika verwandelt, – und RoslinCT, ein weltweit führendes Unternehmen im Bereich der Auftragsentwicklung und -herstellung von Zell- und Gentherapien, kündigten heute die Erweiterung ihrer strategischen Partnerschaft an, die nun auch eine kommerzielle Liefervereinbarung zur Unterstützung der Produktion von Omisirge® (...
-

Resumen: RoslinCT y Ayrmid Ltd. anuncian la ampliación de su alianza estratégica para fabricar Omisirge® (omidubicel-onlv) para una segunda indicación aprobada por la FDA en anemia aplásica grave (AAG)

BOSTON--(BUSINESS WIRE)--Ayrmid Ltd., empresa matriz de Gamida Cell Inc., empresa pionera en terapias celulares especializada en transformar células en potentes tratamientos terapéuticos, y RoslinCT, líder mundial en desarrollo y fabricación por contrato de terapias celulares y génicas, anunciaron hoy la ampliación de su alianza estratégica para incluir la ejecución de un acuerdo de suministro comercial destinado a respaldar la producción de Omisirge® (omidubicel-onlv). El comunicado en el idio...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Indxx NextG UCITS ETF 15.12.2025 NXTG.LN IE00BWTNM743 200,002.00 USD 7,820,502.78 39.102  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Dow Jones International Internet UCITS ETF 15.12.2025 FDNI.LN IE00BT9PVG14 400,002.00 USD 8,962,425.58 22.406  ...